RxDoctor Payments Data

Andrew Pratt

Physician Assistant · San Antonio, TXNPI 1265860159

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,504 of the $86,609 with a category attached, or 74.5%. Neurocrine Biosciences, Inc. accounts for 99.8% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $52,078, more than ten times the $19 reported in 2021. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,609in general payments, 2019–2025

Across 147 payments — averaging $589.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$86K
  • Otsuka America Pharmaceutical, Inc.$42
  • Alkermes, Inc.$37
  • Janssen Scientific Affairs, LLC$32
  • Teva Pharmaceuticals USA, Inc.$21
  • AbbVie$19
  • plus $15 from 1 others

What the payments were for

  • Consulting fees$11,25013%
  • Speaking & faculty fees$64,50474%
  • Travel & lodging$7,3869%
  • Food & beverage$3,4694%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,609 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$357,799
Medicare patients
229
Services billed
5,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate131$713,771
Invega SustennaPaliperidone Palmitate16$54,313
Divalproex Sodium682$26,193
Clonazepam166$3,717
Lorazepam164$3,098
Medroxyprogesterone Acetate30$3,048
Trazodone Hcl261$2,931
Quetiapine Fumarate283$2,862
Oxcarbazepine31$2,777
Risperidone225$2,713
Aripiprazole113$2,562
SeroquelQuetiapine Fumarate11$2,386
Olanzapine117$2,121
Lurasidone Hcl13$1,746
Duloxetine Hcl55$1,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$86,443$713,771131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →